Curanex Pharmaceuticals Inc
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Curanex Pharmaceuticals Inc's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 100%
Sales fell 100% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-100% / +113076%In 3 years sales changed by -100% while total assets changed by +113076%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-85.5×Operating cash was negative last year, while some debt falls due within a year.
Lower than 81% of Healthcare companies in United States.
Cash Cushion Ratio
+57%Cash, after subtracting all debt, equals 57% of its market value (net cash).
Higher than 79% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Curanex Pharmaceuticals Inc made a loss over the last year. Curanex Pharmaceuticals Inc owes $0.06 for every $1 it owns. Curanex Pharmaceuticals Inc made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossCuranex Pharmaceuticals Inc made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.70The share price is 1.70 times Curanex Pharmaceuticals Inc's book value per share, lower than 64% of Healthcare companies in United States.
Market cap
$8 MThe total market value of all of Curanex Pharmaceuticals Inc's shares at today's price (share price × number of shares), smaller than 89% of Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$5 MWhat Curanex Pharmaceuticals Inc would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$3.05Net worth divided by the number of shares. The share price of $5.20 is 1.7 times this, which is the P/B above.
Return on equity (ROE)
-411.1%Curanex Pharmaceuticals Inc lost 411.1% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
Owes vs Owns
0.06×Curanex Pharmaceuticals Inc owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Dividend yield
NoneCuranex Pharmaceuticals Inc does not currently pay a dividend.
Profit growth
LossCuranex Pharmaceuticals Inc made a loss in each of the last two years.
Interest cover
Not coveredCuranex Pharmaceuticals Inc's operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashCuranex Pharmaceuticals Inc held $5 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Curanex Pharmaceuticals Inc: $8 M ÷ $5 M (30 Jun 2026) = 1.7.
What is Curanex Pharmaceuticals Inc's return on equity?
Curanex Pharmaceuticals Inc lost 411.1% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
How much does Curanex Pharmaceuticals Inc owe compared with what it owns?
Curanex Pharmaceuticals Inc owes $0.06 for every $1 it owns (low), lower than 95% of Healthcare companies in United States.
Does Curanex Pharmaceuticals Inc pay a dividend?
No. Curanex Pharmaceuticals Inc does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.